What Might Brazil’s Divisive New President Bring Pharma?
Executive Summary
The Pink Sheet looks at the impact Brazil’s divisive new president elect might have on healthcare and the pharmaceutical industry. Top-level reorganization or depleted healthcare budgets?
You may also be interested in...
Could New Governments In Brazil, Mexico Derail International Regulatory Convergence?
Bayer's Patrick Brady says nationalist sentiments raise concerns, but he remains hopeful that technology and progress will continue to drive globalization.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.